CCCC

C4 Therapeutics Inc.

Price

$3.50

return (12m)

54.65%

p/e

-4.24

p/bv

1.88

DIVIDEND YIELD

0.00%

CCCC price

C4 Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CCCC

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-20.57%

3 months

21.35%

1 year

54.65%

2 years

-45.73%

5 years

-91.73%

10 years

0.00%

Fundamentals CCCC

Valuation

P/E

-4.24

Sector -4.25

Industry -4.25

P/BV

1.88

Sector 2.02

Industry 2.02

P/Revenue (PSR)

12.63

Sector -4.24

Industry -4.24

EV/EBITDA

-7.48

Sector -61,637,555.16

Industry -61,637,555.16

EV/EBIT

-7.37

Sector -37,101,806.96

Industry -37,101,806.96

P/EBITDA

-4.35

Sector -4.42

Industry -4.42

P/EBIT

-4.27

Sector -4.46

Industry -4.46

P/Total Assets

1.34

Sector 1.44

Industry 1.44

P/Ativo Circ. Liq.

2.92

Sector -11,369,656.32

Industry -11,369,656.32

P/Cap.Giro

2.02

Sector -10,584,388.41

Industry -10,584,388.41

EPS

-0.82

Sector -2.26

Industry -2.26

BVPS

1.86

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

100.00%

Sector 36.04%

Industry 36.04%

EBITDA Margin

-445.20%

Sector -16,822.56%

Industry -16,822.56%

EBIT Margin

-451.87%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

-100.00%

Sector -39.46%

Industry -39.46%

Net Profit Margins

-100.00%

Sector -40.60%

Industry -40.60%

Giro Ativos

0.02

Sector 0.03

Industry 0.03

Profitability

ROE

-44.32%

Sector -67.67%

Industry -67.67%

ROA

-31.57%

Sector -67.17%

Industry -67.17%

ROIC

-94.28%

Sector -2,910.52%

Industry -2,910.52%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

9.00

Sector 2.90

Industry 2.90

Dívida Líquida/EBITDA

8.61

Sector -20.78

Industry -20.78

Dívida Líquida/EBIT

8.48

Sector -3.57

Industry -3.57

Dívida Líquida/Patrimônio

-1.01

Sector -1.11

Industry -1.11

Dívida Bruta/Patrimônio

0.00

Sector 0.00

Industry 0.00

Equity/Assets

0.71

Sector 0.41

Industry 0.41

Liabilities/Assets

0.29

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-5.31%

Sector -

Industry -

5Y Earnings CAGR

4.35%

Sector -

Industry -

Fundamentals CCCC

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
CCCC	-4.24	1.88	-44.32%	0.00%	$440.37 M	-100.00%
JNJ	30.06	7.44	24.76%	1.99%	$632.34 B	21.48%
PFE	18.39	1.52	8.29%	7.11%	$137.74 B	11.83%
ABBV	126.05	-69.30	-54.98%	2.60%	$458.19 B	5.79%
NVO	11.83	7.14	60.40%	3.68%	$224.33 B	37.15%
MRK	35.53	6.91	19.45%	2.62%	$317.48 B	13.59%
AZN	25.14	5.51	21.93%	1.90%	$261.15 B	17.19%
GILD	17.54	6.90	39.33%	2.47%	$161.64 B	30.99%
BMY	17.28	6.25	36.19%	4.05%	$125.69 B	15.01%
ZTS	11.99	9.80	81.75%	2.74%	$31.69 B	27.79%
REGN	15.66	2.20	14.08%	0.55%	$69.27 B	29.65%
HALO	27.62	43.86	158.82%	0.00%	$9.63 B	23.13%
AMGN	26.05	22.11	84.87%	2.60%	$203.18 B	20.96%
MCK	21.66	-123.68	-570.98%	0.39%	$103.15 B	1.18%
VRTX	28.04	6.28	22.41%	0.00%	$121.66 B	35.51%
CAH	34.58	-20.13	-58.20%	0.89%	$53.78 B	0.62%
HRMY	14.10	2.26	16.00%	0.00%	$2.05 B	16.20%
BIIB	21.68	1.59	7.36%	0.00%	$29.75 B	13.81%
MEDP	34.42	38.99	113.29%	0.00%	$16.92 B	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CCCC Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT C4 Therapeutics

C4 Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2020

Time since IPO - 6 years

99

Employees

C4 Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $440.37 million, with shareholders equity totaling $234.25 million.

The company employs approximately 99 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, C4 Therapeutics Inc. reported $34.86 million in revenue, generating net income of $-103.81 million.

Key financial metrics include a P/E ratio of -4.24, a price-to-book (P/B) ratio of 1.88, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CCCC.

Market cap

$440.37 million

Net worth

$234.25 million

$234,250,000.00

Assets

$328.86 million

$328,860,000.00

Total Shares Outstanding

126.00 million

126,000,000

Average Daily Trading Volume

$3.40 million

$3,399,538.68

Sector

Health Care

Industry

Biotechnology

CCCC

CCCC revenue and profits

Financial Results CCCC

DRAG THE FRAME TO SEE MORE DATA

CCCC cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

CAH - Cardinal Health

$228.84 47,16% (12M)

P/E

34.58

0.89%

ROE

-58.20%

P/BV

-20.13

JNJ - Johnson & Johnson

$262.71 60,01% (12M)

P/E

30.06

1.99%

ROE

24.76%

P/BV

7.44

AZN - AstraZeneca

$168.59 19,41% (12M)

P/E

25.14

1.90%

ROE

21.93%

P/BV

5.51

ABBV - AbbVie

$258.87 41,59% (12M)

P/E

126.05

2.60%

ROE

-54.98%

P/BV

-69.30

PFE - Pfizer

$24.63 6,30% (12M)

P/E

18.39

7.11%

ROE

8.29%

P/BV

1.52

BMY - Bristol-Myers Squibb

$62.36 35,15% (12M)

P/E

17.28

4.05%

ROE

36.19%

P/BV

6.25

AMGN - Amgen

$376.27 26,40% (12M)

P/E

26.05

2.60%

ROE

84.87%

P/BV

22.11

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

CAH - Cardinal Health

$228.84 47,16% (12 M)

P/L

34.58

0.89%

ROE

-58.20%

P/VP

-20.13

JNJ - Johnson & Johnson

$262.71 60,01% (12 M)

P/L

30.06

1.99%

ROE

24.76%

P/VP

7.44

AZN - AstraZeneca

$168.59 19,41% (12 M)

P/L

25.14

1.90%

ROE

21.93%

P/VP

5.51

ABBV - AbbVie

$258.87 41,59% (12 M)

P/L

126.05

2.60%

ROE

-54.98%

P/VP

-69.30

PFE - Pfizer

$24.63 6,30% (12 M)

P/L

18.39

7.11%

ROE

8.29%

P/VP

1.52

BMY - Bristol-Myers Squibb

$62.36 35,15% (12 M)

P/L

17.28

4.05%

ROE

36.19%

P/VP

6.25

AMGN - Amgen

$376.27 26,40% (12 M)

P/L

26.05

2.60%

ROE

84.87%

P/VP

22.11

Frequently Asked Questions

What is the price of C4 Therapeutics (CCCC) today?

A cotação de C4 Therapeutics (CCCC) hoje está em US$ 3.50, com uma variação de 54.65% em relação ao último ano. A cotação de C4 Therapeutics (CCCC) iniciou o ano negociando na casa dos US$ 1.91 e hoje está em US$ 3.50. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de C4 Therapeutics (CCCC) e dados de ações do Ibovespa e mercados internacionais.

Quando C4 Therapeutics (CCCC) paga dividendos?

C4 Therapeutics (CCCC) não distribuiu dividendos no último ano.

Is C4 Therapeutics (CCCC) a good investment?

Atualmente, C4 Therapeutics (CCCC) está cotada a US$ 3.50, com um P/L de -4.24, representando um desvio de -266% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 54.65 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 54.65%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy C4 Therapeutics (CCCC) stock?

Investir em ações de C4 Therapeutics (CCCC) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of C4 Therapeutics (CCCC) yield today?

A rentabilidade de C4 Therapeutics (CCCC) foi de -20.57% no último mês, 54.65% no último ano e -91.73% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de C4 Therapeutics (CCCC) hoje, o investimento total seria de US$ 349.50, com base na cotação atual de US$ 3.50.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 540.50
Em 5 anos: US$ 28.90
Em 10 anos: US$ 349.50

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CCCC

C4 Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CCCC

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

current DY: 0.00%

5-year average DY: 0.00%

ABOUT C4 Therapeutics

C4 Therapeutics Inc.

United States

11 years

2020

99

PROFIT X PRICE CCCC

Financial Results CCCC

CCCC cash flow

Asset, Revenue and Profit Growth - CCCC

CCCC balance sheet

BFRA - Biofrontera

CAH - Cardinal Health

JNJ - Johnson & Johnson

AZN - AstraZeneca

ABBV - AbbVie

PFE - Pfizer

BMY - Bristol-Myers Squibb

AMGN - Amgen

BFRA - Biofrontera

CAH - Cardinal Health

JNJ - Johnson & Johnson

AZN - AstraZeneca

ABBV - AbbVie

PFE - Pfizer

BMY - Bristol-Myers Squibb

AMGN - Amgen

Frequently Asked Questions